Canaccord Genuity Reiterates a 'Buy' on Inhibitex (INHX); INX-189/Ribavirin Synergy Supports Nuc Potency
Tweet Send to a FriendGet Alerts INHX Hot Sheet
Price: $26.00 --0%
Rating Summary:
5 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Rating Summary:
5 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Trade INHX Now!
Canaccord Genuity reiterates a 'Buy' on Inhibitex (NASDAQ: INHX) price target raised from $15 to $22.00.
Canaccord analyst says, "Increasing our likelihood of 189 approvals in GT2/3 and GT1 HCV treatment subgroups to 40% and 30% from 30% and 20%, respectively, and sticking to an estimated 2015 market launch, we arrive at our new target of $22. For now we see peak 189 sales of $3.7B in 2021 and 40% market share in what could be a $10-15B market for HCV nuc prodrugs. Gilead's (Nasdaq: GILD) intended $11B Pharmasset (Nasdaq: VRUS) acquisition supports this view."
For an analyst ratings summary and ratings history on Inhibitex click here. For more ratings news on Inhibitex click here.
Shares of Inhibitex closed at $13.70 yesterday, with a 52 week range of $2.00-$13.94.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Canaccord analyst says, "Increasing our likelihood of 189 approvals in GT2/3 and GT1 HCV treatment subgroups to 40% and 30% from 30% and 20%, respectively, and sticking to an estimated 2015 market launch, we arrive at our new target of $22. For now we see peak 189 sales of $3.7B in 2021 and 40% market share in what could be a $10-15B market for HCV nuc prodrugs. Gilead's (Nasdaq: GILD) intended $11B Pharmasset (Nasdaq: VRUS) acquisition supports this view."
For an analyst ratings summary and ratings history on Inhibitex click here. For more ratings news on Inhibitex click here.
Shares of Inhibitex closed at $13.70 yesterday, with a 52 week range of $2.00-$13.94.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Morgan Stanley Says Tesla (TSLA) 'Top Pick in U.S. Autos'
- UPDATE: Vanda Pharmaceuticals (VNDA) Opens Higher; Lazard Raises PT to $17
- Needham & Company Remains on Sidelines wth Applied Materials (AMAT) Post Q2
Create E-mail Alert Related Categories
Analyst Comments
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
